TICKERNERD
Menu
ABOSABOSHealthcare · Biotechnology

ABOS Stock Forecast: Acumen Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.92
+2.10% on the day

The 6 Wall Street analysts covering Acumen Pharmaceuticals, Inc. hold a median 12-month price target of $8 — +174.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$211.2M
Ticker Nerd rank
43 / 100
Median analyst target
$8.00
Analysts covering
6
Revenue$0.0
Operating income−$32.6M
Net income−$32.7M
Free cash flow−$18.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.5%
1M
+18.2%
YTD
+38.4%
1Y
+110.1%
From 52W high
−13.4%
From 52W low
+137.4%
$1.23
$3.37
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ABOS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Acumen Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
82
Momentum
82
Accruals
80
Size
67
Revisions
33
Value
30
Volatility
28
Quality
21
Issuance
19

Growth (82): Sales and profits are climbing, and climbing faster than before.

Issuance (19): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ABOS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABOS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26ABOSHigh $10.00Median $8.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $4.00Median $8.00High $10.00

The green dot is the last close — the median target sits +174.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Mar 2026BTIGReiteratesBuy$8.00
16 Mar 2026BTIGMaintainsBuy—
27 Jan 2026BTIGMaintainsBuy—
18 Nov 2025B of A SecuritiesMaintainsBuy—
25 Aug 2025B of A SecuritiesMaintainsBuy—
17 June 2025CitigroupInitiatesBuy—
28 Mar 2025HC Wainwright & Co.MaintainsBuy—
28 Mar 2025UBSMaintainsBuy—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy—
3 Oct 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024UBSMaintainsBuy—
14 Aug 2024HC Wainwright & Co.ReiteratesBuy—
25 July 2024CitigroupInitiatesBuy—
15 May 2024HC Wainwright & Co.ReiteratesBuy—
31 Mar 2024UBSMaintainsBuy—
27 Mar 2024HC Wainwright & Co.MaintainsBuy—
12 Dec 2023Deutsche BankInitiatesBuy—
9 Aug 2023Credit SuisseReiteratesOutperform—
9 Aug 2023HC Wainwright & Co.ReiteratesBuy—
17 July 2023Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABOS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ABOS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Acumen Pharmaceuticals, Inc. returned +110.1% against +17.5% for the S&P 500, dividends included.

ABOS vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Oct 25Jan 26Apr 26Jul 26ABOSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ABOS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Acumen Pharmaceuticals, Inc. (ABOS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.5×

Cheaper than 84% of US stocks

Price / sales
—
Price / book
3.7×

Cheaper than 27% of US stocks

EV / EBITDA
−1.3×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−120.5%

Higher than 11% of US stocks

Return on assets
−45.8%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Acumen Pharmaceuticals, Inc. (ABOS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Acumen Pharmaceuticals, Inc. has a market value of $211.2M and an enterprise value of $132.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$105.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$91.8M.

  • Acumen Pharmaceuticals, Inc. spent $149K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 72.3M.

  • Trailing P/E: −1.5×; forward P/E: −2.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Acumen Pharmaceuticals, Inc. employs 60 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

ABOS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ABOSAcumen Pharmaceuticals, Inc.$211.2M
43
PLXProtalix Biotherapeutics, Inc.$212.7M
89
CUECue Biopharma, Inc.$208.8M
40
NKTXNkarta, Inc.$207.5M
42
SLGLSol-Gel Technologies Ltd.$215.6M
42
PEPGPepGen Inc.$204.8M
46
SRZNSurrozen, Inc.$218.2M
72

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Acumen Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ABOS news & analysis

Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

GlobeNewsWire · 10 Sept 2026neutral

Acumen Pharmaceuticals announced it will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET. The company develops novel therapeutics targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment.

Why it matters — The Investor Day provides an opportunity for ABOS shareholders and watchers to hear directly from the company about its clinical-stage pipeline and development plans.

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 10 Sept 2026neutral

Acumen Pharmaceuticals, Inc. presented at Citigroup's Biopharma Back to School Summit 2026, with the event's transcript published by Seeking Alpha. The presentation covered the company's participation at the industry conference.

Why it matters — ABOS watchers would care because the presentation provides an opportunity to hear directly from the company's leadership at a major industry conference.

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

Acumen Pharmaceuticals announced that its management will participate in several upcoming investor conferences. The clinical-stage biopharmaceutical company, which develops therapeutics targeting toxic soluble amyloid beta oligomers for Alzheimer's disease, disclosed the scheduled appearances in a press release.

Why it matters — ABOS watchers may be interested in these conference appearances as opportunities for management to present the company's Alzheimer's disease program to the investment community.

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 12 Aug 2026neutral

Acumen Pharmaceuticals, Inc. (ABOS) released its Q2 2026 earnings call transcript, as published on Seeking Alpha. The item consists of the transcript of the company's second-quarter earnings call.

Why it matters — A transcript of the Q2 2026 earnings call gives ABOS watchers direct access to management's commentary on the company's recent results and outlook.

Acumen Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 12 Aug 2026neutral

Acumen Pharmaceuticals confirmed it is on track to release top-line results from its Phase II ALTITUDE-AD study of sabirnetug in late 2026 during its Q2 earnings call.

Why it matters — The timeline update provides ABOS watchers with clarity on the expected readout date for the company's lead Alzheimer's candidate, a key catalyst for the stock.

FAQ

Frequently asked questions about ABOS stock

What is the ABOS stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Acumen Pharmaceuticals, Inc. have a median 12-month price target of $8, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABOS stock a buy right now?

Of the 6 analysts covering Acumen Pharmaceuticals, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Acumen Pharmaceuticals, Inc. 43 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABOS?

As at 12 Sept 2026, Acumen Pharmaceuticals, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (82 of 100).

Will ABOS stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +174.0% from the last close, and Ticker Nerd's factor model ranks Acumen Pharmaceuticals, Inc. 43 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABOS stock forecast for 2030?

No analyst covering Acumen Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.

How has ABOS stock performed over the past year?

Acumen Pharmaceuticals, Inc. returned +110.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Acumen Pharmaceuticals, Inc. do?

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease.

What is the latest news on ABOS?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026". Acumen Pharmaceuticals announced it will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET. The company develops novel therapeutics targeting toxic soluble amyloid beta oligomers for Alzheimer's disease treatment.

Company

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease. The company’s lead program centers on sabirnetug (ACU193), an investigational immunotherapy designed to selectively target toxic soluble amyloid beta oligomers, which are believed to contribute to Alzheimer’s pathology. Acumen’s work is aimed at disease-modifying treatment approaches rather than symptom management, with its research and clinical programs concentrated on early symptomatic and mild Alzheimer’s disease. Headquartered in Newton, Massachusetts, Acumen Pharmaceuticals operates within the neuroscience and biotechnology sectors, where it plays a specialized role in advancing antibody-based therapies and diagnostics for neurodegenerative disease.

CEO Mr. Daniel J. O'Connell M.B.A. · 60 employees · United States · https://acumenpharm.com